Fouzia Laghrissi-Thodes

Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017.

DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada.

Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada.

DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada.

DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada.

DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada.

DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada.

DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.